Recent preclinical and clinical research has shown that almorexant promotes sleep in animals and humans without disrupting the sleep architecture. Here, the pharmacology and kinetics of [ 3 H]almorexant binding to human orexin 1 receptor (OX 1 )-and human orexin 2 receptor (OX 2 )-human embryonic kidney 293 membranes were characterized and compared with those of selective OX 1 and OX 2 antagonists, including 1- -408124), and N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA). The effect of these antagonists was also examined in vitro on the spontaneous activity of rat ventral tegmental area (VTA) dopaminergic neurons. [
1998; Sakurai et al., 1998) . They elicit their effect through two G-protein-coupled receptors called OX 1 (hypocretin receptor type 1) and OX 2 (hypocretin receptor type 2). Both OX 1 and OX 2 are coupled via G q/11 to the activation of phospholipase C, leading to an elevation of intracellular Ca 2ϩ levels (Sakurai et al., 1998) . Moreover, OX 2 also couples via G s and G i/o to the cAMP pathways (Tang et al., 2008) . The [ 125 I]orexin-A binding and functional assays demonstrated that orexin-A has a 10-fold greater affinity for OX 1 over OX 2 , whereas orexin-A and -B bind with similar affinity to OX 2 (Sakurai et al., 1998) . Although both OX 1 and OX 2 are expressed in most brain regions, including ventral tegmental area (VTA), dorsal raphe nucleus, laterodorsal tegmental nuclei, pedunculopontine tegmental nuclei, and hypothalamus, OX 1 is most abundantly expressed in the locus ceruleus, whereas OX 2 is expressed in the regions controlling arousal, found abundantly in the tuberomammillary nucleus (Trivedi et al., 1998; Marcus et al., 2001) .
Orexins and their receptors have been implicated in numerous physiological functions, including energy homeostasis, feeding and reward, and regulation of arousal and the sleep-wake cycle (Kilduff and Peyron, 2000; Ohno and Sakurai, 2008) . Because of their depolarizing actions on distinct populations of monoaminergic neurons (Soffin et al., 2004) , OX 1 and OX 2 might have different functions within the central nevous system. Several lines of evidence support the pivotal role of OX 2 in the regulation of sleep-wakefulness: a mutation (canarc-1), which disrupts the gene encoding OX 2 , was found to be responsible for canine narcolepsy (Lin et al., 1999) ; furthermore, intracerebroventricular administration of orexin-A had no effect in narcoleptic dogs, although it significantly increased wakefulness in control dogs (Nishino et al., 2001 ). The orexin-induced wakefulness is largely mediated by the histaminergic system through OX 2 and is almost completely absent in H 1 receptor knockout mice (Huang et al., 2001; Yamanaka et al., 2002 ). Both OX 2 and H 1 receptors are localized in the tuberomammillary nucleus neurons, an important site for the regulation of sleep-wakefulness. OX 2 knockout mice exhibited abnormal attacks of non-REM sleep, marked sleep-wake fragmentation, and cataplexy (Willie et al., 2003) . The selective stimulation of OX 2 by [Ala 11 ]orexin-B (100-fold selectivity for OX 2 over OX 1 ) promoted wakefulness in freely behaving rats (Akanmu and Honda, 2005) . Conversely, a role for OX 1 in feeding and reward and in mediating some of the effects of drugs of abuse has been suggested (Harris et al., 2005; Thorpe and Kotz, 2005; Narita et al., 2006) . The lateral hypothalamic orexin neurons project to reward-associated brain regions, including the nucleus accumbens and VTA, which suggests the involvement of orexins in drug-seeking and other motivational behaviors (Harris et al., 2005; Scammell and Saper, 2005) . It is noteworthy that morphine-induced place preference seen in wild-type mice was abolished in mice lacking the preproorexin gene. The selective OX 1 antagonist SB-334867A, injected in the VTA, was able to block the morphine-conditioned place preference in rats (Narita et al., 2006) . The biochemical characterization of an OX 2 antagonist, EMPA, with 900-fold selectivity in binding for OX 2 over OX 1 has been reported (Malherbe et al., 2009) .
Preclinical (dog and rat) and phase I (healthy male subjects, single dose) investigations have shown that the dual antagonist almorexant (ACT-078573), when administered orally during the active period, promoted sleep (non-REM and REM) in animals and humans without disrupting the sleep architecture or inducing cataplexy (Brisbare-Roch et al., 2007) , thereby further validating the involvement of orexin system in the regulation of alertness and sleep. Here, the pharmacology and kinetics of [ 3 H]almorexant binding to human OX 1 -and OX 2 -expressing membranes were characterized. The antagonistic mechanism of almorexant was determined by Schild analyses using the orexin-A-or orexin-Binduced accumulation of [ 3 H]inositol phosphates (IP) assay in hOX 1 -or hOX 2 -expressing cells. Dopaminergic neurons of the VTA receive a dense projection of orexin neurons from the lateral hypothalamus (Fadel and Deutch, 2002) and are excited by orexin-A (Korotkova et al., 2003) . To define the precise role of OX 1 and OX 2 in the modulation of VTA DA neurons, we conducted electrophysiological recordings in rat midbrain slices. The effects of almorexant, SB-674042, SB-408124 (Langmead et al., 2004) , and EMPA on the spontaneous action potential firing of VTA DA neurons were compared.
Materials and Methods
Materials. Almorexant (ACT-078573; Brisbare-Roch et al., 2007) , EMPA, SB-674042 (Langmead et al., 2004) , Cp-1, Cp-2, Cp-3, Cp-4, and Cp-5 (Hirose et al., 2003) Plasmids, Cell Culture, and Membrane Preparation. cDNA encoding human OX 1 (accession no. O43613) and human OX 2 (accession no. O43614) were subcloned into pCI-Neo expression vectors (Promega, Madison, WI). HEK293 cells were transfected as described previously (Malherbe et al., 2009 ). Forty-eight hours after transfection, cells were harvested and washed three times with cold phosphate-buffered saline and frozen at Ϫ80°C. The pellet was suspended in ice-cold buffer containing 15 mM Tris-HCl, pH 7.5, 2 mM (1ϫ) with GlutaMax1, 4500 mg/l D-glucose and sodium pyruvate, 5% dialyzed fetal calf serum, 100 g/ml penicillin, and 100 g/ml streptomycin. Cells were washed twice in labeling medium: Dulbecco's modified Eagle's medium without inositol (MP Biomedicals, Irvine, CA), 10% dialyzed fetal calf serum, 1% penicillin/streptomycin, and 2 mM glutamate. Cells were seeded at 8 ϫ 10 4 cells/well in poly(D-lysine)-treated 96-well plates in the labeling medium supplemented with 5 Ci/ml myo- [1,2- 3 H]inositol and were incubated overnight. The following day, cells were washed three times with the wash buffer (1ϫ HBSS and 20 mM HEPES, pH 7.4) and then incubated for 10 min at room temperature in assay buffer (1ϫ HBSS, 20 mM HEPES, pH 7.4, 0.1% BSA, plus 8 mM LiCl final, to prevent phosphatidyl-inositide breakdown) before the addition of agonists or antagonists. When present, antagonists were incubated for 20 min at 37°C before stimulation with agonist; concentrations ranged from 0.00003 to 3 M for orexin-A or orexin-B. After 45-min incubation at 37°C with agonist, the assay was terminated by the aspiration of the assay buffer and the addition of 100 l of 20 mM formic acid to the cells. After shaking for 30 min at 23°C, a 40-l aliquot was mixed with 80 l of yttrium silicate beads (12.5 mg/ml) that bind to the inositol phosphates (but not inositol) and shaken for 30 min at 23°C. Assay plates were centrifuged for 2 min at 750g before counting on a Packard Top Count microplate scintillation counter with quenching correction (PerkinElmer Life and Analytical Sciences).
Intracellular Ca 2؉ Mobilization Assay. The CHO(dHFr Ϫ )-OX 1 and -OX 2 stable cells lines were seeded at 5 ϫ 10 4 cells/well in the poly(D-lysine)-treated, 96-well, black/clear-bottomed plates. Twentyfour hours later, the cells were loaded for 1 h at 37°C with 4 M Fluo-4 acetoxymethyl ester in FLIPR buffer (1ϫ HBSS, 20 mM HEPES, and 2.5 mM probenecid). Cells were washed five times with FLIPR buffer to remove excess dye, and then intracellular calcium mobilization ([Ca 2ϩ ] i )was measured using a Fluorometric Imaging Plate Reader (FLIPR-96; Molecular Devices, Sunnyvale, CA) as described previously (Malherbe et al., 2009 ). Orexin-A (50 mM stock solution in DMSO) was diluted in FLIPR buffer plus 0.1% BSA. The EC 50 and EC 80 values of orexin were measured daily from standard agonist concentration-response curves in CHO(dHFr Ϫ )-OX 1 or -OX 2 stable cell line. Inhibition curves were determined by the addition of 11 concentrations (0.0001-10 M in FLIPR buffer) of inhibitory compounds and using EC 80 value of orexin-A as agonist (a concentration that gave 80% of maximum agonist response, determined daily). The antagonists were applied 25 min (incubation at 37°C) before the application of the agonist. Responses were measured as peak increase in fluorescence minus basal, normalized to the maximal stimulatory effect induced by EC 80 value of orexin-A. Inhibition curves were fitted according to the Hill equation y ϭ 100/(1 ϩ (x/IC 50 ) nH ), where n H is the slope factor using Prism 4.0 (GraphPad Software). K b values were calculated according to the following equation:
, where A is the concentration of agonist added that is very close to agonist EC 80 value, and IC 50 and EC 50 values were derived from the antagonist inhibition and orexin agonist curves, respectively.
Electrophysiology in Rat Midbrain Slices. Wistar rats (12-27 days old) were anesthetized in a 2.5% isoflurane/96.5% oxygen mixture for 2 min and decapitated, according to the approved procedure by the local institutional animal welfare committee. The brain was quickly removed, and horizontal midbrain slices (250 m thick) containing the VTA were cut with a vibratome (Leica, Wetslar, Germany) in an ice-cold solution containing 250 mM glycerol, 2.5 mM KCl, 1.2 mM MgCl 2 , 2.4 mM CaCl 2 , 1.2 mM NaH 2 PO 4 , 26 mM NaHCO 3 , and 11 mM D-glucose (335 mOsM). Immediately after cutting, the slices were transferred for 20 min to warm artificial cerebrospinal fluid (ACSF; 35°C) containing 119.0 mM NaCl, 2.5 mM KCl, 1.3 mM MgCl 2 , 2.5 mM CaCl 2 , 1 mM NaH 2 PO 4 , 26.2 mM NaHCO 3 , and 11 mM D-glucose gassed with a mixture of 95% O 2 /5% CO 2 (295 mOsM) and then stored for later use at room temperature. For electrophysiological recordings, a slice was transferred to the recording chamber (volume, ϳ1 ml) containing gassed ACSF held at 35°C and perfused at a rate of 2 ml/min. Neurons were identified visually using a microscope equipped with infrared differential interference contrast optics (Olympus, Basel, Switzerland). Loose The K ob , K off , K on , t 1/2 , and K d values are mean Ϯ S.E. calculated from three independent experiments (each performed in quadruplet) as described under Materials and Methods.
Radioligand and Receptor
Association Kinetic Dissociation Kinetic Apparent
H͔Almorexant ( 622 patch recordings were made from presumed DA neurons that spontaneously fired action potentials, using thin-wall borosilicate glass pipette (Clark GCT150; Warner Instruments, Hamden, CT) filled with ACSF. Signals were filtered (1-Hz high and 2-KHz low pass) and amplified with a Multiclamp 700A amplifier (Molecular Devices) digitized at 10 kHz with a DigiData 1200 interface and stored on a personal computer with the pClamp 8.0 data acquisition software (both from Molecular Devices). A neuron was considered dopaminergic if it had a regular firing pattern (0.5-2 Hz), a broad (Ͼ2 ms) triphasic action potential (Grace and Onn, 1989) , and was sensitive to quinpirole (100 nM), a dopamine receptor agonist. Action potentials were detected by means of threshold search using the Clampfit analysis program (Molecular Devices). The firing frequencies (action potentials per second) were calculated in bins of 1 min. Values are given as mean Ϯ S.E.M., and n represents the number of neurons recorded. In concentration-response experiments, increasing concentrations of orexin-A or quinpirole were perfused in a consecutive manner. For each concentration, maximum firing frequencies were measured and plotted as a function of the concentration. Firing frequencies from each recorded neuron were fitted with the nonlinear least-squares fitting routine of the data analysis program Origin (OriginLab Corp, Northampton, MA) using the equation
, where f is the measured firing frequency, f max is the maximum firing frequency, x is the concentration tested, EC 50 is the half-maximum effective concentration, and n H is the slope factor. Quinpirole concentration-response curves were normalized to the maximum firing frequency. In concentration-response shift experiments, concentration-response curves of orexin-A were generated after incubation of the slices with almorexant for at least 1 h. Drugs were applied to the slices by exchanging the solution of the recording chamber until a maximum effect was reached. All salts for ACSF solutions were obtained from Sigma-Aldrich (Basel, Switzerland). Stock solutions of EMPA, almorexant, SB-408124, and SB- molpharm.aspetjournals.org 674042 (10 mM) were made in DMSO and diluted in gassed ACSF to reach a final concentration of DMSO never exceeding 0.1%. (Fig. 2 , A and C) and hOX 2 (Fig. 2, B 3 H]Cp-1 to hOX 1 was rapid with halfmaximal binding occurring at 3 and 1.1 min and reaching equilibrium within 15 and 10 min, respectively (Fig. 3A) . Likewise, the association kinetics of [ 3 H]almorexant and [ 3 H]Cp-1 to hOX 2 were fast with t 1/2 of 5.3 and 4.0 min, respectively, and reached equilibrium within 30 min for both radioligands (Fig. 3C) . The data from both antagonists were fitted to a one-phase exponential model for hOX 1 and hOX 2 (Fig. 3 , A and C, and Table 2 ).
Results

Binding
The ]SB-674042, the first radioligand antagonist selective for hOX 1 to be described previously (Langmead et al., 2004) , was used in the current study for comparison. [ 3 H]SB-674042 has been characterized previously in saturation and binding kinetics at hOX 1 with whole-cell and membrane-based scintillation proximity assays (Langmead et al., 2004 (Fig. 3F and Table 2 ). The apparent dissociation constant was 0.66 nM, which was similar to the equilibrium K d value of 0.74 nM. The filtration binding data of [
3 H]SB-674042 are in good agreement with those reported previously using whole-cell and scintillation proximity binding assays (Langmead et al., 2004) .
Two different cell systems were used in the current study. HEK293 cells were transiently transfected with hOX 1 and hOX 2 and were used for binding studies, and CHO(dHFr Ϫ )-hOX 1 and -hOX 2 stable cells were used for functional studies (FLIPR and IP accumulation assays). Because HEK293 cells were adapted to grow and to be transiently transfected in suspension in spinner flasks, it was possible to produce and prepare large quantities of transfected cells and membranes required for binding studies. (Hirose et al., 2003) ; and the dual OX 1 /OX 2 antagonists almorexant (BrisbareRoch et al., 2007) , Cp-1, Cp-2, and Cp-3 are shown in Fig. 1 .
Potencies of these antagonists in inhibiting [
3 H]almorexant binding to HEK293-hOX 1 and -hOX 2 cell membranes are shown in Fig. 4 , A and B, with their derived K i and n H values in Table 3 . The apparent antagonist potency (pA 2 ) and Schild slope values were determined from Schild plot analyses shown in Fig. 5, B values of 1.1 and 2.4 nM, respectively. When orexin-A was used as agonist, both almorexant and Cp-1 acted as competitive antagonists at hOX 1 , shifting orexin-A CRCs to the right without changing its maximal response (Fig. 5, A and E). However, when orexin-B was used as agonist, increasing concentrations of almorexant and CP-1 produced a rightward shift along with a partial decrease of maximal response of the orexin-B CRCs (Fig. 5, C and G) . The apparent antagonist potency (pA 2 ) and the Schild slope values calculated from orexin-A and orexin-B Schild analyses (Fig. 5, B , D, F, and H) are given in Table 5 . As seen in Table 5 , there is a good agreement between the functional potencies of almorexant and Cp-1 derived from FLIPR assay (K b ) ( (Table 5 ). In addition, the selective OX 1 antagonists SB-674042, SB-408124, and SB-334867 displayed a noncompetitive-like mode of antagonism at hOX 1 , shifting orexin-A CRCs to the right with a concomitant decrease in maximal response (Fig. 6, A-C) . Likewise, as seen in Fig. 7 , A-D, almorexant and Cp-1 behaved in a noncompetitive manner at hOX 2 and produced a rightward shift along with a full decline of maximal response of both orexin-A and orexin-B CRCs.
Potencies of Various OX Antagonists on Inhibition of
Effect of OX Antagonists on Firing Frequency of Rat VTA DA Neurons. To assess the role of OX antagonists on native OX receptors in brain slices, we performed extracellular recordings of spontaneous activity of DA neurons in the VTA. It has been shown previously that a subset of VTA DA neurons is excited by orexin-A (Korotkova et al., 2003) . These neurons can be identified on the basis of the regular firing frequency, action potential duration, and sensitivity to DA agonists and orexin-A. We first confirmed the dopaminergic nature of some of the recorded neurons. For this, quinpirole, a DA-selective agonist, was tested on inhibition of firing frequency (Fig. 8A) . As expected, quinpirole concentrationdependently inhibited the activity of all neurons tested with an IC 50 of 22 nM (n ϭ 3). However, orexin-A (100 nM) produced an increase in firing frequency up to 175 Ϯ 17% of control in 29 of 48 neurons. This is in keeping with the previously published study (Korotkova et al., 2003) . In concentration-response experiments, orexin-A concentration-dependently increased the firing frequency of three neurons with an EC 50 of 23 nM (Fig. 8B) . To assess the effect of OX antagonists, a near-saturating concentration of orexin-A (100 nM) was used. We first established that repeated applications of orexin-A (100 nM) after complete recovery from the application elicited similar increases of the basal firing frequency without apparent desensitization (n ϭ 4). As shown in Fig. 9A , application of almorexant (1 M) to the slice did not change the basal firing frequency of a representative neuron. In the continuous presence of almorexant, orexin-A (100 nM) did not significantly enhance the basal firing frequency of the neurons after three applications anymore (Fig.  9B) . The time course of antagonism of almorexant was rather slow: the complete reversal of the effect of orexin-A by almorexant occurred after 90 min of perfusion (Fig. 9B) . In five neurons, the firing frequencies in the absence and presence of almorexant were 2.43 Ϯ 0.80 and 2.52 Ϯ 0.70 Hz, respectively. In the same neurons, the increase of firing frequency by orexin-A (100 nM) was 170 Ϯ 29 and 105 Ϯ 2% of control in the absence and presence of almorexant (1 M), respectively (Table 6 ). The ability of almorexant to shift the concentration-response curve of orexin-A for increasing the firing frequency of DA VTA neurons was assessed. In slices incubated for 60 to 70 min with 100 nM almorexant, orexin-A was less potent and efficacious (Fig. 9C) . The EC 50 values for increase of firing frequencies by orexin-A in the absence and presence of almorexant were 29 (n ϭ 5) and 68 nM (n ϭ 6), respectively, and the increase of firing frequency by orexin-A (100 nM) in the absence and presence of almorexant was 269 Ϯ 26 and 186 Ϯ 29% of control, respectively. These experiments demonstrate the antagonistic property of almorexant on the orexin-A-induced increase of firing frequency of DA VTA neurons.
The effect of SB-408124, SB-674042, and EMPA (1 M) on basal firing frequency and on orexin-A-induced increase of firing frequency was assessed using the same experimental paradigm. All three compounds had no effect on basal firing frequency (Table 6 ). EMPA completely reversed the effect of orexin-A. In contrast to almorexant and EMPA, SB-408124 and SB-674042 only partially reversed the effect of orexin-A on the firing frequency of VTA DA neurons (Table 6 ). The time course of the antagonism by EMPA and SB-408124 was (Fig. 10) .
Discussion
Insomnia is the most common sleep disorder, affecting 20% of the general population and having a severe impact on quality of life. Current therapies that are mainly based on GABA A receptor modulation (Bhat et al., 2008) result in several side effects, including disruption of sleep architecture, insufficient sleep maintenance, withdrawal effects, and abuse potential (Roth and Roehrs, 1991) . Recent positive clinical data with almorexant have indicated that this OX antagonist is efficacious in inducing and maintaining sleep without disrupting the sleep architecture (Brisbare-Roch et al., 2007) . Thus, OX antagonists represent an alternative therapeutical approach for the treatment of insomnia (Nishino, 2007; Roecker and Coleman, 2008) . In the present work, we have characterized the pharmacological profile of almorexant and its monoamide analog, Cp-1. . It is noteworthy that Cp-1 displayed a 14-fold decrease in binding affinity at hOX 1 , yet only a 2.4-fold decrease at hOX 2 compared with almorexant. As shown previously, the peptide agonist orexin-A distinctly recognizes OX 1 from OX 2 (Ammoun et al., 2003; Takai et al., 2006) . It was concluded that orexin-A binding to OX 1 requires more molecular determinants than binding to OX 2 . Therefore, as demonstrated in the present study with Cp-1, minor modifications in the chemical structure of almorexant are expected to have a more pronounced effect on the binding affinity of the modified compound to OX 1 than that to OX 2 .
Binding 3 H]almorexant binding with the following rank order of potencies: SB-674042ϾCp-2ϾalmorexantϾCp-3Ͼ Cp-1ϾSB-408124ϾSB-334667ϾCp-4ϾEMPAϾCp-5 from HEK293-hOX 1 membranes and Cp-1ϾalmorexantϾEMPAϾ Cp-2ϾCp-4ϾCp-3ϾCp-5ϾSB-674042ϾSB-408124ϾSB334867 from HEK293-hOX 2 membranes. These results are consistent with the rank order of potencies of these ligands in inhibiting orexin-A-evoked [Ca 2ϩ ] i response at hOX 1 and hOX 2 . Investigation of the antagonistic mechanism of almorexant and Cp-1 revealed that both compounds act as competitive antagonists at hOX 1 in the presence of orexin-A as agonist but display a tendency toward a partial noncompetitive like mode in the presence of orexin-B. As further evidence, the Schild slopes of 1.80 and 1.69 for almorexant and Cp-1 at OX 1 , respectively, show a deviation from simple competitive antagonism with unit slope. However, almorexant and Cp-1 behaved in a noncompetitive manner at hOX 2 . This mode of action, independent of the agonist used, was characterized by a rightward shift of the orexin-A or orexin-B concentrationresponse curves in the presence of increasing almorexant or Cp-1 concentrations with a concomitant large decrease in the maximal effect of orexin-A or orexin-B. A possible explanation for the noncompetitive-like antagonism of almorexant at hOX 2 determined by Schild plot analyses may be its remarkably slow dissociation rate from hOX 2 that was observed in the kinetic study. Because of almorexant's slow dissociation, a large portion of the OX 2 is not available for activation by orexin-A or orexin-B; consequently, the maximally achievable response of orexin-A or orexin-B decreases dramatically -fold selectivity in FLIPR assay for hOX 1 over hOX 2 , respectively) showed that all behaved in a noncompetitive like manner at hOX 1 , similarly to that of almorexant at hOX 2 . The noncompetitive-like mode of antagonism of these compounds was also characterized by a very steep hill slope (n H values of 3.3, 3.5, and 2.0 for SB-33486, SB-408124, and SB-674042, respectively) observed in the FLIPR assay using hOX 1 -expressing cells. The binding kinetics of [
3 H]SB-674042 further demonstrated that SB-674042 has a slow dissociation rate (the reversal of the binding was complete with a t 1/2 value of 32 min, at 23°C) at hOX 1 , which could also account for its noncompetitive-like mode of antagonism observed in the orexin-A-evoked accumulation of [ 3 H]IP assay. Neurons containing orexins from the lateral hypothalamus strongly innervate the ventral tegmental area (Fadel and Deutch, 2002; Baldo et al., 2003) , and electrophysiological recordings have shown previously that both orexin-A and orexin-B increase the firing rate of VTA neurons (Korotkova et al., 2003) . Although orexins act on two types of VTA neurons, dopaminergic (characterized by slow firing frequency of ϳ2.2 Hz and broad action potential of Ͼ2 ms) and GABAergic (characterized by rapid firing frequency of ϳ7.3 Hz and brief action potential of Ͻ1.5 ms), yet they preferentially activate VTA dopamine (A10) neurons projecting to the nucleus accumbens and prefrontal cortex (Korotkova et al., 2003) . In the current study, the effect of OX antagonists almorexant, SB-408124, SB-674042, and EMPA on firing frequency of rat VTA DA neurons were examined by loosepatch electrophysiological technique. In the VTA, the majorities of neurons fired action potentials with a slow frequency and were sensitive to quinpirole, a D 2 receptor agonist. Orexin-A increased the basal firing frequency of responsive DA VTA neurons in concentration-response experiments, with an EC 50 of 23 nM. A value of the same order of magnitude has been reported previously (78 nM) (Korotkova et al., 2003) . In the present study, only approximately half of the DA neurons examined were responsive to orexin-A. A recent study demonstrated that orexin neurons preferentially activate caudomedial ventral tegmental area dopamine neurons (Vittoz et al., 2008) . Because we did not select DA neurons from this particular subregion of the VTA, it is very possible that a certain number of the recorded neurons were not responsive to orexin-A.
The OX antagonists tested in this study had no intrinsic effect on the spontaneous activity of VTA DA neurons. Almorexant completely reversed the effect of orexin-A on the firing frequency of DA neurons in the VTA. This was achieved with a saturating concentration (1 M) of almorexant blocking both OX 1 and OX 2 . In concentration-response shift experiments performed at a lower almorexant concentration (100 nM), a rightward shift of the orexin-A CRC along with a decrease of maximal response was observed. This noncompetitive behavior of almorexant is in good agreement with its pseudo-irreversible mode of antagonism at OX 2 , which is seen in Schild plot analyses using the [ 3 H]IP assay and in OX 2 binding kinetic studies. EMPA (a highly potent and selective OX 2 ) (Malherbe et al., 2009 ) did also completely reverse the increase in firing frequency of these neurons. However, at the concentration tested, this antagonist acts only at OX 2 . This suggests that OX 2 are sufficient to mediate the excitatory effects of orexin neurons on the VTA DA neurons. This complex behavior of selective OX antagonist in the VTA neurons might well indicate the formation of heterodimers/oligomers by both receptors. Indeed, the residue hOX 2 -Val308 (corresponds to hOX 1 -Val302, located on the transmembrane 6 on the outer surface of the receptor) seems to be involved in OX 2 dimerization, and the 1246GϾA polymorphism (substitution of valine 308 by isoleucine) of the OX 2 gene has been suggested to modulate the genetic risk for cluster headaches by interfering with this dimerization process (Rainero et al., 2008) . Furthermore, a report investigating the coexpression of OX 1 and cannabinoid CB1 has shown that the heterodimerization of OX 1 -CB1 receptors resulted in both ligand-dependent and -independent coordinated alterations of receptor localization and function (Ellis et al., 2006) .
It is noteworthy that a recent investigation comparing almorexant, SB-408124, and the selective OX 2 antagonist JNJ-10397049 in sleep modulation in rats has demonstrated that although both JNJ-10397049 and almorexant induced and prolonged sleep time (non-REM and REM), the selective OX 2 antagonist had a 10-fold higher potency than dual OX 1 /OX 2 antagonist. On the contrary, SB-408124 had no effect on any sleep parameter tested, and it attenuated the sleep-promoting effect of OX 2 antagonist when it was coadministered with JNJ-10397049 (Dugovic et al., 2009) .
In the present study, the OX 1 -selective antagonists SB-408124 and SB-674042 only partially reversed the effect of orexin-A. However, in vivo administration of the OX 1 antagonist SB-334867 blocked the locomotor sensitization to cocaine and occluded the cocaine-induced potentiation of excitatory currents in VTA dopamine neurons (Borgland et al., 2006) . Therefore, the lesser contribution of OX 1 on orexin-A-mediated increase of firing frequency in the VTA can still account for robust in vivo effects. It has been hypothesized that orexin neurons may play an important role in modulating the reward process (Harris and AstonJones, 2006) . Thus, in addition to a remedy for sleep disorders, selective OX antagonists might also be promising molecules for the treatment of addiction. In conclusion, almorexant exhibited a noncompetitive and long-lasting pseudo-irreversible mode of antagonism as a result of its very slow rate of dissociation from OX 2 . The electrophysiology data suggest that OX 2 might be more important than OX 1 in mediating the effect of orexin-A on slow firing of VTA dopaminergic neurons. 
